Early results of a phase I study at Virginia G. Piper Cancer Center in Scottsdale, Arizona, collaborating with researchers at the Karmanos Cancer Institute in Detroit, Michigan, and the Dana-Farber Cancer Institute in Boston, Massachusetts, showed promise for a new drug that targets the P13k gene.
20- to 30-percent of patients with advanced breast cancer have the abnormal gene. The study of various advanced cancers, including breast, indicated that the new drug was successful in shrinking tumors with tolerable side effects.
Testing patients for the gene mutation is the next step in order to identify those who might benefit from treatment with the new drug, GDC-0941, manufactured by Genentech, San Francisco. Dr. Dr. Daniel D. Von Hoff presenting the findings at the annual conference of the American Society of Clinical Oncology (ASCO) in June 2011.
5 6 7 8
© 2004–2011 Donna Peach. All rights reserved.